Floatz logo

FULVESTRANT

Breast Cancer - Male

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoSmall moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Breast Cancer - Male cohort.

Asset / SponsorPhaseRating
LEUPROLIDE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 3BB
Zoladex
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 3BB
Ribociclib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 1CC

Same molecule, other indications

FULVESTRANT is also rated in:

Hormone Receptor Positive TumorDormant
BB
Indicative ·
70 / 100
View asset →
hormone receptor-positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Progesterone Receptor PositiveDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →